ABSTRACT BOOK ABSTRACTS



A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

MELANOMA AND MELANOCYTIC NAEVI

## CONTRIBUTION OF EUROMELANOMA ON IMPROVING THE QUALITY OF MELANOMA DIAGNOSIS IN RUSSIA IN 10 YEARS PROSPECT.

Ekaterina Chepurina<sup>(1)</sup> - Irina Korsunskaya<sup>(1)</sup>

Russian Academy Of Sciences, Centre Of Theoretical Problems Of Physico-chemical Pharmacology, Moscow, Russian Federation<sup>(1)</sup>

Melanoma is a malignant tumor of neuroectodermal origin, developing from melanocytes located mainly in the skin and characterized by an extremely aggressive course. From the structure of all tumors, melanoma composes not more than 10%, but it is responsible for 80% of deaths. The reason for this phenomenon is that melanoma is characterized not only by local recurrence or the appearance of regional lymphogenous metastases, but also hematogenous metastasis with the development of distant metastases.

Early diagnosis of melanoma is crucial for the patient.

In 2007, Russia joined to the initiative of European dermatologists - Euromelanoma Day, which aims to draw attention to the problem of skin cancer and its early diagnosis.

The participation in the Euromelanoma Day contributed to the introduction into clinical practice of dermatoscopy as a method with high diagnostic accuracy, allowing visualize of intradermal changes in the lesions and giving them an objective assessment.

In the ten years of this event in Russia, the number of participating doctors increased from 105 to 1,200, which made it possible to examine 12,073 patients, in comparison with 2,292 patients in 2007.

In 2007, only some dermatologists used dermatoscopy for the diagnostic of the pigmented skin neoplasms and they assessed lesions only based on the visual signs; suspicions on melanoma were identified in 10% of patients. In major of cases, it was overdiagnosis.

In 2017, dermatoscopy was applied in 88% of cases and among the examined patients, clinical signs of melanoma were detected in 1% of patients, clinical signs of dysplastic nevus - in 2% of patients and basal cell carcinoma - in 1%.

Melanoma Day also allows to study the epidemiological features of melanoma.

Thus, the Euromelanoma Day could be considered as a set of measures addressed both to patients and doctors, which acquires an important social significance.





